Navigation Links
NeurogesX Appoints New Board Director and Audit Committee Chairman
Date:8/25/2009

SAN MATEO, Calif., Aug. 25 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the appointment of Bradford S. Goodwin to its Board of Directors as a director and Audit Committee chairman, effective August 20, 2009. Mr. Goodwin currently serves as President and CEO of Keren Pharmaceutical, a company focused on exploiting a novel, Nobel Prize winning method of gene silencing. He also serves as nonexecutive chairman of Facet Biotech Corp. and as a director of Rigel, Inc.

Following Mr. Goodwin's appointment, NeurogesX received a letter dated August 21, 2009 from the Listing Qualifications Staff of the Nasdaq. The letter indicated that the Company has regained compliance with Nasdaq's audit committee composition requirements for continued listing as set forth in Listing Rule 5605(c)(2)(A), which requires that the Company's Audit Committee be comprised of at least three members, each of whom are independent.

Mr. Goodwin is a healthcare industry veteran and has held executive positions and board seats at several biopharmaceutical companies. Prior to joining Keren Pharmaceutical, he served as Chief Executive Officer and director of Novacea, Inc. from 2001 to 2006. Previously, Mr. Goodwin was President, Chief Operating Officer and Co-founder of Collabra Pharma. Before starting Collabra, Mr. Goodwin held various senior executive positions over a 12-year tenure at Genentech, Inc., including Vice President of Finance, and was responsible for treasury, purchasing, risk management, real estate, controllership, tax and long-range planning.

In addition Mr. Goodwin has held nonexecutive chairman positions at CoTherix, Inc. and PDL BioPharma
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NeurogesX Reports Second Quarter 2009 Results
2. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
3. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
4. NeurogesX Added to Russell 3000 Index
5. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
6. NeurogesX to Present at Needham Life Sciences Conference
7. NeurogesX Receives European Commission Approval for Qutenza(TM)
8. NeurogesX Reports First Quarter 2009 Results
9. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
10. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
11. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)...  GenVec, Inc. (NASDAQ: GNVC ) today announced ... its board of directors effective on October 24, 2014.   Dr. ... as its chairman from June 2006 to November 2013.  During ... Governance and Audit Committees of the board.  ... dedicated service to GenVec, and its stockholders," said Wayne ...
(Date:10/20/2014)... N.J. (PRWEB) October 20, 2014 ... the Sidney Kimmel Cancer Center at Thomas Jefferson ... , Through the Strategic Alliance Partnership program, ... OncLive will collaborate to raise awareness of the ... treatment, and other projects. Clinicians and other health ...
(Date:10/20/2014)... OR (PRWEB) October 20, 2014 Local ... participate in an investigational study of donor stem cells ... in stem cell therapy and has performed clinical stem ... this study is to determine if a single injection ... affected joints can help reduce pain and inflammation in ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 ... Industry Meeting (ABIM). ABIM will take ... More information about ABIM 2014 is now ... , Delegates representing companies and organizations from ... and obtain information on the latest products ...
Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... - It has yet to turn a profit, and it operates ... but the decision by Madison research tool manufacturer NimbleGen Systems ... $75 million is the latest bit of evidence that the Wisconsin ... continues a pattern of growth and visibility for NimbleGen, which saw ...
... Glendale, Wis. - When it comes to health information ... side" of Wheaton Franciscan Healthcare is thinking. , ... system, has plenty of insights into the business side of ... administration, he once founded a computer resource business, and now ...
... spending in the healthcare industry is soaring, as are ... privacy, computerized physician order entry , and the ... operations faced by CIOs in other industries. , ,The ... what separates the men from the boys is that ...
Cached Biology Technology:IPO-bound NimbleGen traveling in fast company 2IPO-bound NimbleGen traveling in fast company 3IPO-bound NimbleGen traveling in fast company 4CIO Leadership Series: Greg Smith, Wheaton Franciscan Healthcare 2CIO Leadership Series: Greg Smith, Wheaton Franciscan Healthcare 3CIO Leadership Series: Greg Smith, Wheaton Franciscan Healthcare 4Fire your CIO? If he's not implementing strategy, show him the door 2Fire your CIO? If he's not implementing strategy, show him the door 3
(Date:10/18/2014)... with undiagnosed, suspected genetic conditions, a certain type of ... diagnostic yield than traditional molecular diagnostic methods, according to ... is being released to coincide with the American Society ... sequences the protein­coding region of the genome (the complete ... cell or organism), has been rapidly applied in research ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
(Date:10/17/2014)... . To date, ... overdoses, doctors are often limited to supportive therapy such as ... combination of drugs involved. So what can be done if ... ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences ... question. "The task was to develop an agent that could ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... Corporate Safe Specialists (CSS),announces an addition to ... Ladd as National Account Manager., (Photo: ... James Currey, Sales Manager of the Company, stated, ... further accelerate the growth we,ve seen in,networked safe ...
... long observed that when food becomes scarce, animal populations ... studying southern sea otters at different sites in California,s ... dietary diversity of the population is higher where food ... the diets of individual sea otters, which instead showed ...
... discovered some of the genetic secrets that enable ... and disease, uncovering critical new information about forests ... says this genetic analysis will allow forest stewardship ... trees that could in time repel insects such ...
Cached Biology News:Corporate Safe Specialists Announces Addition to Sales Team 2Sea otter study reveals striking variability in diets and feeding strategies 2Sea otter study reveals striking variability in diets and feeding strategies 3UBC discovery unlocks tree genetics, gives new hope for pine beetle defense 2
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap, packed in double bag. (20/ca) Packaging: ...
... The Yeast Protein Kit is a simple ... of yeast cells. The kit has been optimized ... but can be used for any fungus species ... The Zymolyase digestion procedure effectively generates spheroplasts of ...
... is a pleiotropic cytokine produced by activated ... OSM inhibits the growth of some tumour ... muscle and Kaposis sarcoma cell proliferation, cytokine ... lipoprotein receptor expression on hepatoma cells. Mouse ...
... used for heterologous protein expression in the ... cell line was derived from a primary culture ... melanogaster embryos (1). This versatile cell ... and is easily adapted to suspension culture. ...
Biology Products: